Bristol-myers Squibb And Astrazeneca
PARIS and LONDON, March 4, 2011 - Bristol-Myers Squibb Company (www.bms.com)(NYSE: BMY) and
AstraZeneca (www.astrazeneca.com) (NYSE: AZN)today announced that the
European Commission has approved a label update for ONGLYZA(R) (saxagliptin)
in the treatment of adults with type 2 diabetes who have moderate or severe
renal impairment.
PARIS and LONDON, March 4, 2011 - In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor
Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by
Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would
like to advise that the headline was incorrectly transmitted by
PR Newswire and should have read "ONGLYZA(R) Becomes the First DPP-4
Inhibitor Available for Use in Europe in Type 2 Diabetes Patients With
Moderate or Severe Renal Impairment" rather than "ONGLYZA(R) Becomes the
First DPP-4 Inhibitor Available for Use in Europe".
ORLANDO, Florida, June 26, 2010 - Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a
Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy
with metformin, which produced long-term glycemic improvement [as measured
by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with
type 2 diabetes mellitus inadequately controlled on diet and exercise
compared to treatment with an investigational 10 mg dose of saxagliptin or
metformin alone.
ORLANDO, Florida, June 26, 2010 - Bristol-Myers Squibb Company (NYSE: BMY)
and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b
study in adults with type 2 diabetes who had inadequate glycemic control on
metformin therapy plus diet and exercise.
ORLANDO, Florida, June 26, 2010 - Results from a 24-week Phase 3 clinical
study demonstrated that the addition of the investigational drug
dapagliflozin achieved reductions in the primary endpoint, glycosylated
hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients
who were treated with insulin (with or without oral anti-diabetes medications
(OADs)), compared to placebo plus insulin (with or without OADs).
